Ralliant (NYSE:RAL) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Ralliant to “strong buy” from “hold,” while the broader analyst consensus remains “Moderate Buy” with a $75.70 target price.
• Ralliant exceeded quarterly expectations, reporting $0.68 in EPS on $567.8 million in revenue, and provided fiscal 2026 adjusted EPS guidance of $2.76–$2.90.
• Shares traded around $65.78, while investors also noted potential upside from analyst target increases and planned cost savings of $50 million–$60 million annually by 2028.

Ralliant (NYSE:RAL - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a report released on Monday.

RAL has been the subject of a number of other reports. Citigroup upped their price target on shares of Ralliant from $81.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday. Zacks Research upgraded shares of Ralliant from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, June 30th. Evercore initiated coverage on shares of Ralliant in a research note on Tuesday, June 9th. They set an "outperform" rating and a $80.00 target price on the stock. Oppenheimer upped their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Ralliant in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $75.70.

Ralliant Trading Up 0.6%

Shares of NYSE:RAL opened at $65.78 on Monday. The stock has a 50 day moving average of $67.20 and a 200 day moving average of $54.35. The company has a market cap of $7.36 billion, a PE ratio of -6.06, a price-to-earnings-growth ratio of 2.69 and a beta of 1.61. Ralliant has a 12-month low of $37.27 and a 12-month high of $75.41. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75.

Ralliant (NYSE:RAL - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities research analysts expect that Ralliant will post 2.88 EPS for the current year.

Institutional Trading of Ralliant

A number of large investors have recently added to or reduced their stakes in RAL. Dodge & Cox raised its holdings in shares of Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company's stock worth $621,849,000 after acquiring an additional 1,434,376 shares in the last quarter. Viking Global Investors LP purchased a new position in shares of Ralliant in the second quarter valued at $257,200,000. Millennium Management LLC grew its holdings in shares of Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock valued at $253,175,000 after purchasing an additional 3,147,660 shares in the last quarter. State Street Corp bought a new stake in Ralliant in the second quarter worth $213,096,000. Finally, Invesco Ltd. increased its position in Ralliant by 4.9% in the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company's stock worth $206,674,000 after purchasing an additional 187,898 shares during the last quarter.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.